RESEARCH MONOGRAPH · KDC-MN-303

17-alpha-Estradiol

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

66/100

The non-feminizing estradiol stereoisomer that quietly extends male mouse lifespan and nobody fully understands why

17-alpha-estradiol is one of the more genuinely interesting longevity research compounds of the last fifteen years, and the mechanism remains substantially unclear even now. It's the stereoisomer of estradiol with the 17-alpha hydroxyl instead of the 17-beta, and that single configurational difference drops the affinity for the classical estrogen receptors (ERalpha, ERbeta) by roughly 100-fold while retaining various tissue-selective effects that are mediated through GPR30, mitochondrial pathways, and some non-classical estrogen signaling routes that are still being mapped.

The data that put this compound on the map is the NIA Interventions Testing Program work. Repeated independent replications across multiple sites showed lifespan extension in male mice with chronic 17-alpha-estradiol, with the effect specifically gender-restricted (no significant effect in females), and the magnitude was in the 10-20 percent median lifespan extension range depending on dose and starting age. The Strong/Miller/Harrison ITP papers are the reference, and the replication across multiple cohorts and sites is what makes this interesting rather than dismissable.

What's still unclear is the mechanism. The leading hypotheses are: tissue-selective signaling through GPR30 that overlaps with metabolic flexibility pathways, modulation of hepatic insulin signaling (Garratt/Stout papers on liver-specific effects), and reduction of systemic inflammation in male-specific ways that the ITP frailty markers tracked. None of these have nailed down to a clean single mechanism the way some other longevity interventions have.

What we like: replicated lifespan data across multiple sites, gender-specificity that's mechanistically informative even if not fully understood, and a compound with negligible classical estrogen receptor activation that distinguishes it cleanly from estradiol itself. The metabolic phenotype data is genuinely interesting.

What we dont love is the translation question. The mouse data is consistent but human data is essentially absent. The compound has not been developed clinically, and the dose-equivalence and pharmacokinetic translation to primates is genuinely uncertain. Whether the male-specific effect persists in primates with different gonadal axis baseline is an open question.

Sourcing is decent. 17-alpha-estradiol is small, well-characterized, and reliably synthesized. Research-grade material from competent suppliers is straightforward, HPLC purity is verifiable, and the stereochemistry QC is the one thing to confirm explicitly (the 17-beta contamination is the failure mode you actually care about).

Evidence: 60
Mechanism: 55
Reliability: 70
Safety: 70
Sourcing: 75
Value: 65
Signal: 65
Staying power: 65

Plain-language summary Intrigue 75 / 100

17-alpha-Estradiol is the mirror-image isomer of regular estradiol, identical except for the orientation of one hydroxyl group. That single difference makes it bind classical estrogen receptors about 100 times more weakly, eliminating most of the feminizing effects. The reason it appears in longevity literature: the NIA Interventions Testing Program (a multi-laboratory rodent screening program designed to spot real lifespan-extending drugs) reproducibly showed that 17-alpha-estradiol extends male mouse lifespan by about 12 percent, with no effect in females. The mechanism is incompletely understood, possibly involving non-classical estrogen receptors or hypothalamic effects. One of a handful of compounds with replicated ITP data, but no human trials. Genuinely intriguing sleeper. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Non-feminizing estradiol stereoisomer

The 17-alpha-stereoisomer of estradiol; a non-feminizing estrogen with reported male-specific lifespan extension in NIA Interventions Testing Program studies.

Abstract

17-alpha-estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; molecular formula C18H24O2; molecular weight 272.39) is the 17-alpha-stereoisomer of estradiol, distinguished from the canonical 17-beta-estradiol by the orientation of the hydroxyl group at carbon 17. The compound has minimal affinity for classical estrogen receptors ER-alpha and ER-beta (approximately 100-fold weaker than 17-beta) and lacks meaningful feminizing effects. Despite the receptor inactivity, the NIA Interventions Testing Program demonstrated reproducible male-specific lifespan extension in 17-alpha-estradiol-fed mice across multiple sites. The mechanism is debated; proposed contributors include reduced inflammation, improved insulin sensitivity, modulation of liver gene expression, and effects through membrane estrogen receptors or non-classical pathways. The female-mouse failure suggests sex-specific pharmacology not yet fully characterized. The compound is occasionally used in human longevity contexts despite no clinical trial validation. Used as the canonical non-feminizing estrogen with longevity activity.

Mechanism of action

17-alpha stereoisomer of estradiol; approximately 100-fold weaker classical ER affinity. Non-feminizing. Lifespan extension in male (not female) mice via incompletely characterized mechanisms.

Reported research dose ranges

Mouse studies 14.4 ppm in food (approximately 2 mg/kg equivalent); human dosing is exploratory.

References

Strong R, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 2016.
Garratt M, et al. Sex differences in lifespan extension with 17-alpha-estradiol. Aging Cell 2017.
Stout MB, et al. 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice. Aging 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-303

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

17-alpha-Estradiol

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs